

**Amendments to the Claims:**

Claims 27, 44, 46, 50 and 51 are amended. New claims 59 - 69 are presented.

This listing of claims will replace all prior versions, and listings, of claims in the application.

This Amendment replaces the March 13, 2006 amendment and Response to Final Office Action, which was not entered and should not be entered.

**Listing of Claims:**

1. - 26. (canceled).

27. (currently amended). An isolated ~~C140 receptor~~ polypeptide having a ~~consecutive sequence of at least 15 amino acids~~ at least 15 consecutive amino acids and is encoded by a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of : (a) a nucleic acid molecule complimentary to SEQ ID NO:3, and (b) a nucleic acid molecule complimentary to SEQ ID NO:62, wherein the stringent conditions are: (1) hybridization in 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl and 75 mM sodium citrate at 42°C; or (2) hybridization in 50% formamide, 5 X SSC (750 mM NaCl, 75mM sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 X Denhardt's solution, sonicated salmon sperm DNA (50 ~~g/ml~~ µg/ml), 0.1% SDS, and 10% dextran sulfate 42°C, with washes at 42°C in 0.2 X SSC and 0.1% SDS or with washes at 50°C in 15 mM NaCl, 1.5 mM sodium citrate, and 0.1% sodium dodecyl sulfate, ~~wherein the polypeptide has cross reactive antigenicity to at least 15 amino acids of the amino acid sequence of SEQ ID NO: 4, or 63.~~

28. (previously presented). The isolated polypeptide of claim 27, wherein the polypeptide comprises at least about 75% amino acid sequence identity with either of SEQ ID NOS: 4, or 63.

29. - 43. (canceled)

44. (currently amended). An isolated polypeptide comprising an amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO: 63, ~~wherein the polypeptide has cross-reactive antigenicity to at least 15 amino acids of the amino acid sequence of SEQ ID NO:4 or SEQ ID NO: 63.~~

45. (previously presented). The isolated polypeptide of claim 44, wherein the polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 4.

46. (currently amended). An isolated fragment of a polypeptide selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:63, wherein the fragment ~~comprises~~ is at least 10 consecutive amino acids in length.

47. (previously presented). The isolated fragment of claim 46 consisting of a fragment of SEQ ID NO:63.

48. (previously presented). The isolated polypeptide of claim 44 which comprises the amino acid sequences of SEQ ID NO:63.

49. (previously presented). The isolated polypeptide of claim 45 which comprises the amino acid sequence of SEQ ID NO:4.

50. (currently amended). The isolated polypeptide of claim 27, wherein the polypeptide comprises at least about 90% amino acid sequence identity with ~~either of~~ SEQ ID NO: 4.

51. (currently amended). The isolated polypeptide of claim 27, wherein the polypeptide comprises at least about 90% amino acid sequence identity with ~~either of~~ SEQ ID NO: 63.

52. (previously presented). The isolated polypeptide of claim 27, wherein the polypeptide comprises an activated C140 receptor.
53. (previously presented). The isolated fragment of claim 46 encoded by a nucleic acid molecule comprising nucleotides 56-1249 of SEQ ID NO: 3.
54. (previously presented). The isolated fragment of claim 46 encoded by a nucleic acid molecule comprising nucleotides 50-1240 of SEQ ID NO: 62.
55. (previously presented). The isolated fragment of claim 46, comprising amino acids 1-37 of SEQ ID NO: 4, or amino acids 1-36 of SEQ ID NO: 63.
56. (previously presented). The isolated fragment of claim 46, comprising amino acids 31-37 of SEQ ID NO: 4, or amino acids 30-36 of SEQ ID NO: 63.
57. (previously presented). The isolated fragment of claim 46, comprising at least 20 amino acids in length.
58. (previously presented). The isolated fragment of claim 46, comprising at least 40 amino acids in length.
59. (new). The polypeptide of claim 27 wherein the polypeptide has a biological activity in common with C140.
60. (new). The polypeptide of claim 59 wherein the biological activity is a C140 receptor function.
61. (new). The polypeptide of claim 59 wherein the biological activity is a C140 effector function.

62. (new). The polypeptide of claim 59 wherein the biological activity is cross-reactive antigenicity with C140.
63. (new). An isolated polypeptide comprising the fragment according to claim 46.
64. (new). The polypeptide of claim 63 wherein the fragment is a fragment of SEQ ID NO:63.
65. (new). The polypeptide of claim 63 wherein the fragment is a fragment of SEQ ID NO:4.
66. (new). The polypeptide of claim 63 comprising amino acids 1-37 of SEQ ID NO: 4, or amino acids 1-36 of SEQ ID NO: 63.
67. (new). The polypeptide of claim 63 comprising amino acids 31-37 of SEQ ID NO: 4, or amino acids 30-36 of SEQ ID NO: 63.
68. (new). The polypeptide of claim 63, wherein the polypeptide is at least 20 amino acids in length.
69. (new). The polypeptide of claim 63, wherein the polypeptide is at least 40 amino acids in length.